prnewswire.com
Neutralwww.prnewswire.com ·
eisai projects leqembi revenue to total jpy 143 5 billion for fiscal year 2026 april 2026 march 2027 302773354
WB_1458_HEALTH_PROMOTION_AND_DISEASE_PREVENTIONWB_635_PUBLIC_HEALTHWB_1464_HEALTH_OF_THE_DISABLEDECON_STOCKMARKET
Topic context
This topic has been covered 368158 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedRevenue projection for Leqembi, an Alzheimer's antibody, indicates strong commercial uptake and royalty income for BioArctic. The mechanism is product-specific revenue growth for a biotech firm, with no broader supply chain or scarcity implications.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Eisai projects Leqembi revenue of JPY 143.5 billion for FY2026, a 63% increase YoY.
- BioArctic expects ~SEK 880 million in royalties from Leqembi sales.
- Leqembi is approved in 53 countries for Alzheimer's disease.
- BioArctic and Eisai are preparing joint commercialization in the Nordic region.
- BioArctic's Q1 2026 report is due May 20, 2026.
